FDA's stand on Provenge riles cancer patients

The FDA's decision to demand more data on Dendreon's cancer drug Provenge--after an advisory committee had recommended approval--has energized a host of prostate cancer patients. Advocacy groups have been raising their voices to protest--and in some cases make death threats--over what they see as a last hope for late-stage prostate cancer. Doctors have joined their voices to the chorus and some lawmakers have called for a probe of the decision. Regulators say there's no proof that it works. Patients say it's their only hope to add a couple of months to their lives.

- read the article from the Los Angeles Times

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.